-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

A Targeted Therapeutic Approach for Relapsed or Refractory FLT3m+ AML Patients

Program: Product Theaters
Session: A Targeted Therapeutic Approach for Relapsed or Refractory FLT3m+ AML Patients
Sunday, December 6, 2020, 11:00 AM-12:00 PM

Ramon V. Tiu, MD

Astellas Pharma US, Inc., Northbrook, IL

Disclosures: No relevant conflicts of interest to declare.

See more of: A Targeted Therapeutic Approach for Relapsed or Refractory FLT3m+ AML Patients
See more of: Product Theaters